Related Experiment Video

Updated: Jul 7, 2026

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity
09:32

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Published on: October 17, 2025

Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity

Charles M Rudin1, Wanqing Liu, Apurva Desai

  • 1Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, David H. Koch Cancer Research Building, Room 544, 1550 Orleans St, Baltimore, MD 21231, USA. rudin@jhmi.edu

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|March 4, 2008
PubMed
Abstract

Insights

Genetic factors influence erlotinib toxicity. Specific ABCB1 and EGFR gene variations impact drug levels and are linked to skin rash and diarrhea, aiding personalized cancer treatment strategies.

Area of Science:

  • Pharmacogenomics
  • Clinical Pharmacology
  • Oncology

Background:

  • Erlotinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, is used to treat various cancers.
  • Skin rash and diarrhea are primary dose-limiting toxicities associated with erlotinib treatment.

Purpose of the Study:

  • To investigate the pharmacogenomic and pharmacokinetic factors influencing skin rash and diarrhea caused by erlotinib.
  • To identify genetic variations that predict erlotinib toxicity.

Main Methods:

  • A prospective study involving 80 cancer patients treated with erlotinib.
  • Assessment of erlotinib pharmacokinetics and toxicity.
  • Genotyping of polymorphic loci in EGFR, ABCG2, CYP3A4, and CYP3A5 genes.

Main Results:

  • A novel ABCG2 promoter diplotype associated with lower ABCG2 levels correlated with higher erlotinib exposure (AUC, Cmax).
  • Skin rash variability was linked to trough erlotinib concentration and an EGFR intron 1 polymorphism.
  • Diarrhea variability was associated with EGFR promoter polymorphisms, independent of erlotinib concentration.

Conclusions:

  • A combined pharmacogenomic and pharmacokinetic model helps identify determinants of erlotinib-induced skin and gastrointestinal toxicities.
  • Findings may inform clinical trial design and dose adjustments for erlotinib and similar agents.
  • Further research on germline polymorphisms in EGFR and their impact on EGFR inhibitor efficacy and toxicity is recommended.

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Drug toxicity: Idiosyncratic Reactions01:16

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...